(以下内容从上海证券《医药生物行业周报:罗伐昔替尼达成高额独家授权协议,创新药BD交易持续活跃》研报附件原文摘录)主要观点2026年3月4日,中国生物制药宣布与赛诺菲就罗伐昔替尼达成独家授权协议。根据协议,中国生物制药子公司正大天晴授予赛诺菲在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。中国生物制药有权获得最高15.3亿美元的付款,其中包括1.35亿美元的首付款以及潜在开发、监管及销售里程碑...
Source Link(以下内容从上海证券《医药生物行业周报:罗伐昔替尼达成高额独家授权协议,创新药BD交易持续活跃》研报附件原文摘录)主要观点2026年3月4日,中国生物制药宣布与赛诺菲就罗伐昔替尼达成独家授权协议。根据协议,中国生物制药子公司正大天晴授予赛诺菲在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。中国生物制药有权获得最高15.3亿美元的付款,其中包括1.35亿美元的首付款以及潜在开发、监管及销售里程碑...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.